# Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma

> **NCT02181634** · PHASE2 · COMPLETED · sponsor: **PrECOG, LLC.** · enrollment: 74 (actual)

## Conditions studied

- Cholangiocarcinoma

## Interventions

- **DRUG:** Nab-Paclitaxel and Gemcitabine

## Key facts

- **NCT ID:** NCT02181634
- **Lead sponsor:** PrECOG, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2016-09-24
- **Final completion:** 2017-10-01
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2018-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181634, "Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02181634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*